Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

Phase 2 Enrolling by invitation 260 enrolled Edgewise Therapeutics, Inc. Medpace, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

EDG-5506-203 MESA is an open-label extension study to assess the long-term effect of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults and adolescents with Becker muscular dystrophy

Timeline

Start: 2023-11-02
Primary completion: 2031-02
Completion: 2031-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sevasemten	Small molecule	—	Oral

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

Summary

Timeline

Drugs

Indications